LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)
Percutaneous Treatment of Very LONG Native Coronary Lesions With Drug-Eluting Stent-VI: Everolimus-eluting Versus Zotarolimus-Eluting Stents
Sponsor: Abbott
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Abbott
Other Coronary Artery Disease trials with similar outcome
This PHASE4 trial investigates Coronary Artery Disease and is currently terminated or withdrawn. Abbott leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 2 earlier versions
-
Mar 2017 — Jun 2018 [monthly]
Terminated PHASE4
Status: Active Not Recruiting → Terminated
-
Jan 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
- CardioVascular Research Foundation, Korea
- Seung-Jung Park
For direct contact, visit the study record on ClinicalTrials.gov .